Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Mucopolysaccharidosis I, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, X-linked disease, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 2, mucopolysaccharidosis type 6, nervous system disorder	Active, not recruiting	Phase 1 / Phase 2	2026-02-02		NCT03153319

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	11
McGill University Health Centre/Research Institute of the McGill University Health Centre	139

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The Lundquist Institute at Harbor-UCLA Medical Center	Torrance	United States	2